The U.S. Republican Party on Monday approved a new policy platform that calls for reinstating the 1933 Glass-Steagall law requiring the separation of commercial and investment banking, an addition White House hopeful Donald Trump’s campaign said it backed.
Trump, who will formally accept the Republican presidential nomination in Cleveland this week, has vowed to dismantle most of the Dodd-Frank Wall Street reform law that was passed under President Barack Obama following the 2007-2009 financial crisis.
The language in the Republican platform offered further details on Trump’s regulatory policies.
Trump, who has sought to cast himself as a populist, has accused presumptive Democratic presidential nominee Hillary Clinton of being too close to Wall Street. Her husband, former President Bill Clinton, signed the legislation that repealed Glass-Steagall in 1999.
“The Obama-Clinton years have passed legislation that has been favorable to the big banks, which is why you see all the Wall Street money going to her,” Paul Manafort, Trump’s campaign manager, told reporters on Monday. “They know she’s their champion, and they are supporting her fully.”
Some U.S. lawmakers in both parties support a modern Glass-Steagall to keep banks from becoming “too big to fail,” or so big their collapse would destabilize the financial system. The Democratic Party’s 2016 platform, which has not been approved, calls for an updated version.
Republicans universally despise Dodd-Frank, which their platform calls “Democrats’ legislative Godzilla.” But senior congressional Republicans back other alternatives.
“Glass-Steagall is dumb politics and dumb economics,” said Tony Fratto, who worked in the administration of Republican President George W. Bush. “Returning to Glass-Steagall would be destructive and unworkable.”
Clinton has said she would break up banks based on risk, not size, and frequently focuses on the risks posed by non-bank institutions.
Manafort listed the Glass-Steagall language among platform points he said “reflect the issues that Mr. Trump has raised during the course of the campaign,” including building a wall at the border with Mexico and calling for tougher trade deals.
The platform also calls for control of national parks and other lands to be handed over to states, an effort by the party’s conservative wing that got national attention during a 2014 standoff involving a Nevada cattle rancher.
(Reporting by Emily Stephenson; Editing by Toni Reinhold and Jonathan Oatis)
Democrats and Never-Trumpers gaming out ‘doomsday scenarios’ if president refuses to leave office: report
According to a report in the New York Times, Democratic strategists and Never-Trumper conservatives fear Donald Trump will refuse to leave office should he lose in November and are making plans and figuring out their legal options should such an unprecedented state of affairs come to pass.
The report, by the Times' Reid Epstein, begins with one such possible scenario.
‘Retaliation plain and simple’: Vaccine agency top Doc fired by Trump administration files whistleblower complaint
Dr. Rick Bright has retained an attorney and will be filing a whistleblower complaint after the Trump administration fired him from his position as head of the federal agency charged with developing a COVID-19 vaccine. Dr. Bright was moved to a different agency with a narrower focus after he raised concerns over President Donald Trump's obsession with promoting hydroxychloroquine, a malaria drug recent studies found doubles the death rate in coronavirus patients.
Checking blood for coronavirus antibodies – 3 questions answered about serological tests and immunity
Coronavirus testing in the United States is moving into a new phase as scientists begin looking into people’s blood for signs they’ve been infected by SARS-CoV-2, the virus that causes COVID-19. This technique is called serological testing.
Virologist Daniel Stadlbauer helped develop a serological test to detect SARS-CoV-2 antibodies and helped transfer it from the research lab to the clinical setting. Epidemiologist Aubree Gordon regularly uses serological assays in her research studies on influenza and dengue fever. She’s now established serological testing for SARS-CoV-2 in her research lab.